Spread the love

–News Direct–

Redx Pharma PLC (AIM:REDX) CEO Lisa Anson discusses the enrollment of the first participant in its RXC008 Phase 1 clinical trial in an interview with Proactive's Stephen Gunnion.

RXC008 is a 'first-in-class' ROCK inhibitor, designed to be gut-restricted, targeting fibrostenotic Crohn's disease. This oral molecule inhibits ROCK1 and ROCK2, aiming to avoid systemic side effects like hypertension, and providing targeted action in the gut. This development marks a significant step from laboratory to patient-focused clinical development.

Anson highlighted the unmet need for Crohn's disease treatment, particularly for patients with fibrostenotic complications, where currently no drug treatments are available, leaving surgery as the only option.

The next steps for the RXC008 programme include escalating doses in healthy volunteers, with plans to move into patient trials towards the end of the year. Additionally, Anson mentioned Redx Pharma's broader portfolio, noting that RXC008 is the sixth molecule from Redx to enter clinical trials, showcasing the company's drug discovery prowess.

Other key developments include the Phase 2 trials of RXC007 for lung fibrosis and RXC004 for cancer, both expected to report data this year.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

[email protected]

View source version on newsdirect.com: https://newsdirect.com/news/redx-pharma-achieves-milestone-with-dosing-of-first-participant-in-phase-1-clinical-trial-for-rxc008-195462833

Redx Pharma PLC

comtex tracking


Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Times World USA journalist was involved in the writing and production of this article.

Categories: Cloud PRWire